1. Introduction — sets the context of the modern trial landscape and the Bhattacharjee Protocol's four-decade clinical record, framing them as convergent rather than competing.
2. The Modern Trial Landscape — detailed treatment of each trial class: EMPA-KIDNEY/DAPA-CKD, FIDELIO-DKD/FIGARO-DKD, and the PROTECT trial, with their mechanisms and key endpoints.
3. The Bhattacharjee Protocol: Mechanistic Framework — the six mechanistic domains the protocol operates across, described in clinical terms.
4. Parallel Analysis — the heart of the article. Each trial class is paired directly with its homoeopathic parallel in prose, followed by a dark-header comparison table, and closed with an italicised mechanistic note. Sections 4.1 through 4.4 cover hyperfiltration, fibrosis, mesangial protection, and the six clinical-specific medicines (Terebinthina Q, Thlaspi Q, Sabal Q, Arsenicum 200, Equisetum 200, Sarsaparilla 200) each with a dedicated paragraph.
5. Convergence Table — a full 10-row reference table mapping every trial endpoint to its Bhattacharjee remedy and protocol mechanism.
6. Discussion — addresses the convergence conceptually, notes where the protocol covers ground no pharmacological agent currently addresses, and frames the relationship as complementary.
7. Conclusion — closes with the core thesis: same destination, different mechanistic languages.